JP2018532737A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018532737A5 JP2018532737A5 JP2018519702A JP2018519702A JP2018532737A5 JP 2018532737 A5 JP2018532737 A5 JP 2018532737A5 JP 2018519702 A JP2018519702 A JP 2018519702A JP 2018519702 A JP2018519702 A JP 2018519702A JP 2018532737 A5 JP2018532737 A5 JP 2018532737A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- substituted
- ring members
- substituents
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021132047A JP7254127B2 (ja) | 2015-10-21 | 2021-08-13 | ベンゾラクタム化合物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1518676.0 | 2015-10-21 | ||
| GBGB1518676.0A GB201518676D0 (en) | 2015-10-21 | 2015-10-21 | Benzolactam compounds |
| GB1611351.6 | 2016-06-30 | ||
| GBGB1611351.6A GB201611351D0 (en) | 2016-06-30 | 2016-06-30 | Benzolactam compounds |
| PCT/IB2016/001507 WO2017068412A1 (en) | 2015-10-21 | 2016-10-20 | Benzolactam compounds as protein kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021132047A Division JP7254127B2 (ja) | 2015-10-21 | 2021-08-13 | ベンゾラクタム化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018532737A JP2018532737A (ja) | 2018-11-08 |
| JP2018532737A5 true JP2018532737A5 (enExample) | 2019-11-28 |
| JP6931646B2 JP6931646B2 (ja) | 2021-09-08 |
Family
ID=57218943
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018519702A Active JP6931646B2 (ja) | 2015-10-21 | 2016-10-20 | ベンゾラクタム化合物 |
| JP2021132047A Active JP7254127B2 (ja) | 2015-10-21 | 2021-08-13 | ベンゾラクタム化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021132047A Active JP7254127B2 (ja) | 2015-10-21 | 2021-08-13 | ベンゾラクタム化合物 |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US10457669B2 (enExample) |
| EP (1) | EP3365334B1 (enExample) |
| JP (2) | JP6931646B2 (enExample) |
| KR (1) | KR102769567B1 (enExample) |
| CN (2) | CN108617166B (enExample) |
| AU (2) | AU2016341520C1 (enExample) |
| CA (1) | CA3001799A1 (enExample) |
| DK (1) | DK3365334T3 (enExample) |
| ES (1) | ES2989326T3 (enExample) |
| FI (1) | FI3365334T3 (enExample) |
| HR (1) | HRP20241210T1 (enExample) |
| HU (1) | HUE068392T2 (enExample) |
| IL (2) | IL291017B2 (enExample) |
| LT (1) | LT3365334T (enExample) |
| MA (1) | MA47013A (enExample) |
| MX (1) | MX382927B (enExample) |
| MY (1) | MY204050A (enExample) |
| PH (1) | PH12018500792A1 (enExample) |
| PL (1) | PL3365334T3 (enExample) |
| PT (1) | PT3365334T (enExample) |
| SA (1) | SA518391342B1 (enExample) |
| SG (1) | SG10201912959QA (enExample) |
| SI (1) | SI3365334T1 (enExample) |
| TW (1) | TWI747846B (enExample) |
| WO (1) | WO2017068412A1 (enExample) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
| US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
| JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
| MX382355B (es) | 2015-04-10 | 2025-03-13 | Araxes Pharma Llc | Compuestos de quinazolina sustituidos y métodos de uso de los mismos. |
| EP3283462B1 (en) | 2015-04-15 | 2020-12-02 | Araxes Pharma LLC | Fused-tricyclic inhibitors of kras and methods of use thereof |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| WO2017058728A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| US10689356B2 (en) | 2015-09-28 | 2020-06-23 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| EP3356351A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EP3356349A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017058792A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356347A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
| US10457669B2 (en) | 2015-10-21 | 2019-10-29 | Otsuka Pharmaceutical Co., Ltd. | Benzolactam compounds as protein kinase inhibitors |
| EP3377481A1 (en) | 2015-11-16 | 2018-09-26 | Araxes Pharma LLC | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| CN110818690B (zh) | 2016-07-26 | 2021-08-10 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物 |
| KR102537985B1 (ko) | 2016-09-12 | 2023-05-30 | 인테그랄 헬스 인코퍼레이티드 | Gpr120 조정제로서 유용한 단환형 화합물 |
| EP3509588B1 (en) | 2016-09-12 | 2023-06-07 | Integral Health,Inc. | Bicyclic compounds useful as gpr120 modulators |
| EP3519402A1 (en) | 2016-09-29 | 2019-08-07 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| US10377743B2 (en) * | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
| CN106588884B (zh) * | 2016-11-10 | 2019-04-09 | 浙江大学 | 2-多取代芳环-嘧啶类衍生物及制备和医药用途 |
| CN110382482A (zh) | 2017-01-26 | 2019-10-25 | 亚瑞克西斯制药公司 | 稠合的杂-杂二环化合物及其使用方法 |
| US11358959B2 (en) | 2017-01-26 | 2022-06-14 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| EP3573954A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| US11136308B2 (en) | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
| WO2018140513A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
| JP2020521741A (ja) | 2017-05-25 | 2020-07-27 | アラクセス ファーマ エルエルシー | がんの処置のための化合物およびその使用の方法 |
| CN110831933A (zh) | 2017-05-25 | 2020-02-21 | 亚瑞克西斯制药公司 | 喹唑啉衍生物作为突变kras、hras或nras的调节剂 |
| CN110869358A (zh) | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | Kras的共价抑制剂 |
| SG11202002032SA (en) | 2017-09-22 | 2020-04-29 | Jubilant Epipad LLC | Heterocyclic compounds as pad inhibitors |
| CA3076476A1 (en) | 2017-10-18 | 2019-04-25 | Jubilant Epipad LLC | Imidazo-pyridine compounds as pad inhibitors |
| BR112020008851A2 (pt) | 2017-11-06 | 2020-10-20 | Jubilant Prodel LLC | composto da fórmula i, processo de preparação de compostos da fórmula i, composição farmacêutica, método para o tratamento e/ou prevenção de várias doenças, uso, método para o tratamento de câncer, método de tratamento de câncer e método para o tratamento e/ou prevenção de câncer e doenças infecciosas |
| PL3704120T3 (pl) | 2017-11-24 | 2024-09-16 | Jubilant Episcribe Llc | Związki heterocykliczne jako inhibitory prmt5 |
| JP2021509897A (ja) * | 2018-01-03 | 2021-04-08 | メッドシャイン ディスカバリー インコーポレイテッド | Ｃｓｆ−１ｒ阻害剤としての複素環式化合物及びその使用 |
| SG11202008950PA (en) | 2018-03-13 | 2020-10-29 | Jubilant Prodel LLC | Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation |
| EP3773670A4 (en) * | 2018-04-05 | 2022-03-09 | Tarveda Therapeutics, Inc. | HSP90 TARGETING CONJUGATES AND FORMULATIONS THEREOF |
| AU2019272303B2 (en) * | 2018-05-22 | 2024-11-07 | Js Innomed Holdings Ltd. | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof |
| US10934279B2 (en) | 2018-06-13 | 2021-03-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
| BR112021001709A2 (pt) | 2018-08-01 | 2021-05-04 | Araxes Pharma Llc | compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer |
| CN109377846B (zh) * | 2018-10-11 | 2020-12-08 | 内蒙古科技大学包头医学院 | 人体解剖学内脏标本的制作方法 |
| CN109608444B (zh) * | 2018-11-27 | 2022-02-11 | 中国药科大学 | 含异吲哚啉酮的erk抑制剂及其制备方法与用途 |
| CN118834204A (zh) | 2018-12-18 | 2024-10-25 | 阿斯利康(瑞典)有限公司 | 制药方法和中间体 |
| CN111057048B (zh) * | 2019-01-30 | 2022-03-18 | 上海凌达生物医药有限公司 | 一类氨基吡嗪/吡啶类化合物、制备方法和用途 |
| JP7426398B2 (ja) * | 2019-02-26 | 2024-02-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｒａｓ阻害剤としての新規イソインドリノン置換インドールおよび誘導体 |
| AU2020253385B2 (en) * | 2019-04-03 | 2025-06-26 | Fusion Pharmaceuticals Inc. | Hsp90-binding conjugates and formulations thereof |
| CN113825757B (zh) * | 2019-05-24 | 2023-10-20 | 江苏恒瑞医药股份有限公司 | 取代的稠合双环类衍生物、其制备方法及其在医药上的应用 |
| CN113544130B (zh) * | 2019-05-31 | 2024-01-09 | 西藏海思科制药有限公司 | 一种btk抑制剂环衍生物及其制备方法和药学上的应用 |
| WO2021028645A1 (en) | 2019-08-09 | 2021-02-18 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| WO2021055728A1 (en) | 2019-09-18 | 2021-03-25 | Merck Sharp & Dohme Corp. | Small molecule inhibitors of kras g12c mutant |
| CN112574207B (zh) * | 2019-09-30 | 2023-04-11 | 南京药石科技股份有限公司 | Erk1/2蛋白激酶抑制剂及其用途 |
| IL291783A (en) | 2019-10-02 | 2022-06-01 | Domain Therapeutics | ep4 prostaglandin e2 receptor antagonists |
| CA3158793A1 (en) | 2019-10-28 | 2021-05-06 | Merck Sharp & Dohme Corp. | Small molecule inhibitors of kras g12c mutant |
| JP2023515235A (ja) | 2019-10-31 | 2023-04-12 | 大鵬薬品工業株式会社 | ４－アミノブタ－２－エンアミド誘導体及びその塩 |
| WO2021106231A1 (en) | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| CN114829365B (zh) * | 2019-12-06 | 2023-04-25 | 南京明德新药研发有限公司 | 作为erk抑制剂的噻唑并内酰胺类化合物及其应用 |
| US20230174518A1 (en) | 2020-04-24 | 2023-06-08 | Taiho Pharmaceutical Co., Ltd. | Kras g12d protein inhibitors |
| WO2021215545A1 (en) | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c |
| CA3177298C (en) * | 2020-04-30 | 2023-11-21 | Xile LIU | Compounds containing benzosultam as erk inhibitors |
| WO2021224818A1 (en) * | 2020-05-08 | 2021-11-11 | Pfizer Inc. | Isoindolone compounds as hpk1 inhibitors |
| EP4206199A4 (en) * | 2020-08-21 | 2024-08-28 | Shanghai Ringene BioPharma Co., Ltd. | Aromatic ring-lactam compound, preparation method therefor and use thereof |
| CN114516856B (zh) * | 2020-11-20 | 2025-05-23 | 安徽中科拓苒药物科学研究有限公司 | 二氢异喹啉酮和异吲哚啉酮衍生物及其用途 |
| JP2024515964A (ja) * | 2021-04-26 | 2024-04-11 | オハイオ ステート イノベーション ファウンデーション | 脂質ナノ材料及びその使用 |
| WO2022250170A1 (en) | 2021-05-28 | 2022-12-01 | Taiho Pharmaceutical Co., Ltd. | Small molecule inhibitors of kras mutated proteins |
| WO2022253186A1 (zh) * | 2021-06-02 | 2022-12-08 | 南京明德新药研发有限公司 | 一种二甲基取代的噻唑并吡咯酮类化合物的晶型及其制备方法 |
| EP4352052A1 (en) | 2021-06-11 | 2024-04-17 | Otsuka Pharmaceutical Co., Ltd. | Process for preparing an erk inhibitor |
| WO2023039548A1 (en) * | 2021-09-10 | 2023-03-16 | Fred Hutchinson Cancer Center | Kinase inhibitors for the treatment of prostate cancer |
| WO2023076305A1 (en) | 2021-10-26 | 2023-05-04 | Otsuka Pharmaceutical Co., Ltd. | Compositions comprising an erk inhibitor |
| CA3267147A1 (en) | 2022-09-13 | 2024-03-21 | Amphista Therapeutics Limited | COMPOUNDS FOR THE TARGETED DEGRADATION OF A PROTEIN |
| JP2025534418A (ja) * | 2022-09-29 | 2025-10-15 | 蘇州愛科百発生物医薬技術有限公司 | 含窒素縮合複素環化合物、その調製方法、および医薬におけるその使用 |
| CN119790049A (zh) * | 2022-09-30 | 2025-04-08 | 楚浦创制（武汉）医药科技有限公司 | 2-氨基嘧啶类化合物及其应用、药用组合物 |
| WO2024220866A1 (en) * | 2023-04-19 | 2024-10-24 | Accutar Biotechnology Inc. | Novel aminopyrimidine derivatives as cyclin-dependent kinase inhibitors |
| WO2025085748A1 (en) | 2023-10-20 | 2025-04-24 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras proteins |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US5463063A (en) | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
| US5958934A (en) | 1996-05-23 | 1999-09-28 | Syntex (U.S.A.) Inc. | Aryl pyrimidine derivatives and uses thereof |
| WO1999050249A2 (en) | 1998-04-01 | 1999-10-07 | Du Pont Pharmaceuticals Company | Pyrimidines and triazines as integrin antagonists |
| WO2002102313A2 (en) | 2001-06-19 | 2002-12-27 | Bristol-Myers Squibb Company | Pyrimidine inhibitors of phosphodiesterase (pde) 7 |
| DE602004008762T2 (de) | 2003-04-30 | 2008-06-12 | The Institutes for Pharmaceutical Discovery, LLC, Branford | Substituierte heteroarylverbindungen als inhibitoren von proteintyrosinphosphatasen |
| US7504401B2 (en) | 2003-08-29 | 2009-03-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
| WO2005020921A2 (en) | 2003-08-29 | 2005-03-10 | Exelixis, Inc. | C-kit modulators and methods of use |
| DK3305776T3 (da) | 2004-05-14 | 2019-12-09 | Vertex Pharma | Pyrrol-forbindelser som inhibitorer af erk-protein-kinaser og farmaceutiske sammensætninger, der indeholder disse forbindelser |
| WO2006113769A1 (en) | 2005-04-15 | 2006-10-26 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| RU2442778C9 (ru) | 2005-12-13 | 2012-08-10 | Шеринг Корпорейшн | Новые соединения, действующие как ингибиторы erk |
| US20080280891A1 (en) | 2006-06-27 | 2008-11-13 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
| US8258129B2 (en) | 2006-07-06 | 2012-09-04 | Boehringer Ingelheim International Gmbh | 4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments |
| WO2008008059A1 (en) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents ans uses thereof |
| WO2008124085A2 (en) | 2007-04-03 | 2008-10-16 | Exelixis, Inc. | Methods of using combinations of mek and jak-2 inhibitors |
| WO2009017838A2 (en) | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
| US20090082368A1 (en) | 2007-09-24 | 2009-03-26 | Painceptor Pharma Corporation | Methods of modulating neurotrophin-mediated activity |
| EP2573080A1 (en) * | 2007-09-27 | 2013-03-27 | The United States of America, as Represented by the Secretary, Department of Health and Human Services | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
| KR20100110367A (ko) | 2008-01-24 | 2010-10-12 | 메르크 파텐트 게엠베하 | 당뇨병 치료를 위한 베타-아미노산 유도체들 |
| NZ603525A (en) | 2008-06-27 | 2015-02-27 | Celgene Avilomics Res Inc | Pyrimidine based compound and uses thereof |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| GB0815369D0 (en) | 2008-08-22 | 2008-10-01 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| GB0821307D0 (en) | 2008-11-21 | 2008-12-31 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| ES2443948T3 (es) | 2008-12-19 | 2014-02-21 | Bristol-Myers Squibb Company | Compuestos de carbazol carboxamida útiles como inhibidores de quinasas |
| US8716326B2 (en) | 2009-05-15 | 2014-05-06 | Korea Research Institute Of Chemical Technology | Isoindolinone derivatives, preparation method thereof and a pharmaceutical composition comprising same |
| WO2010151747A1 (en) | 2009-06-26 | 2010-12-29 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimine compounds and methods of making and using same |
| WO2011008931A2 (en) | 2009-07-15 | 2011-01-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders |
| EP3309152B1 (en) | 2009-12-22 | 2020-09-09 | Vertex Pharmaceuticals Incorporated | Isoindolinone inhibitors of phosphatidylinositol 3-kinase |
| WO2011075784A1 (en) * | 2009-12-23 | 2011-06-30 | Peter Maccallum Cancer Institute | Compounds, preparations and uses thereof |
| CA2785948A1 (en) | 2009-12-31 | 2011-07-07 | Piramal Healthcare Limited | Inhibitors of diacylglycerol acyl transferase |
| CA2804225C (en) | 2010-07-02 | 2018-05-01 | Aska Pharmaceutical Co., Ltd. | Heterocyclic compound and p27kip1 degradation inhibitor |
| KR101764952B1 (ko) | 2010-07-29 | 2017-08-03 | 리겔 파마슈티칼스, 인크. | Ａｍｐｋ-활성화 헤테로시클릭 화합물 및 그의 사용 방법 |
| US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| HRP20180591T1 (hr) | 2012-03-01 | 2018-05-18 | Array Biopharma, Inc. | Inhibitori kinaze serina ili treonina |
| SI3459942T1 (sl) * | 2012-04-24 | 2021-05-31 | Vertex Pharmaceuticals Incorporated | Inhibitorji DNA-PK |
| CN104583195B (zh) | 2012-09-12 | 2018-08-17 | 山东亨利医药科技有限责任公司 | 作为酪氨酸激酶抑制剂的含氮杂芳环衍生物 |
| WO2014055634A1 (en) | 2012-10-02 | 2014-04-10 | Yale University | Identification of small molecule inhibitors of jumonji at-rich interactive domain 1a (jarid1a) and 1b (jarid1b) histone demethylase |
| KR102229478B1 (ko) | 2012-11-01 | 2021-03-18 | 인피니티 파마슈티칼스, 인코포레이티드 | Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료 |
| US9561228B2 (en) | 2013-02-08 | 2017-02-07 | Celgene Avilomics Research, Inc. | ERK inhibitors and uses thereof |
| US20140357636A1 (en) | 2013-02-21 | 2014-12-04 | Wayne Rothbaum | Treatment of Skeletal-Related Disorders |
| KR102232595B1 (ko) | 2013-08-30 | 2021-03-26 | 피티씨 테라퓨틱스, 인크. | 치환된 피리미딘 bmi-1 저해제 |
| US20150087673A1 (en) | 2013-09-26 | 2015-03-26 | Rigel Pharmaceuticals, Inc. | Methods for using and biomarkers for ampk-activating compounds |
| WO2015108861A1 (en) | 2014-01-14 | 2015-07-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| RU2016141934A (ru) | 2014-04-04 | 2018-05-07 | Сирос Фармасьютикалз, Инк. | Ингибиторы циклин-зависимой киназы 7 (cdk7) |
| WO2015157556A1 (en) | 2014-04-09 | 2015-10-15 | Kadmon Corporation, Llc | Treatment of gvhd |
| WO2016025649A1 (en) | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Combinations of an erk inhibitor and a dot1l inhibitor and related methods |
| TWI704151B (zh) | 2014-12-22 | 2020-09-11 | 美商美國禮來大藥廠 | Ｅｒｋ抑制劑 |
| WO2016162325A1 (en) | 2015-04-07 | 2016-10-13 | Astrazeneca Ab | Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1 (2h)-one derivatives as kinase inhibitors |
| RU2017139727A (ru) | 2015-06-15 | 2019-07-16 | АСАНА БАЙОСАЙЕНСИЗ, ЭлЭлСи | Гетероциклические ингибиторы erk1 и erk2 и их применение для лечения злокачественного новообразования |
| CA2987914C (en) * | 2015-06-30 | 2022-09-13 | Dana-Farber Cancer Institute, Inc. | Inhibitors of egfr and methods of use thereof |
| US10457669B2 (en) | 2015-10-21 | 2019-10-29 | Otsuka Pharmaceutical Co., Ltd. | Benzolactam compounds as protein kinase inhibitors |
| ME03770B (me) | 2015-11-09 | 2021-04-20 | Astrazeneca Ab | Derivati dihidroimidazopirazinona korisni za upotrebu u tretmanu raka |
| CN110818690B (zh) | 2016-07-26 | 2021-08-10 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物 |
| GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
| EP4352052A1 (en) * | 2021-06-11 | 2024-04-17 | Otsuka Pharmaceutical Co., Ltd. | Process for preparing an erk inhibitor |
| WO2023076305A1 (en) * | 2021-10-26 | 2023-05-04 | Otsuka Pharmaceutical Co., Ltd. | Compositions comprising an erk inhibitor |
-
2016
- 2016-10-20 US US15/767,775 patent/US10457669B2/en active Active
- 2016-10-20 MX MX2018004643A patent/MX382927B/es unknown
- 2016-10-20 PL PL16788794.2T patent/PL3365334T3/pl unknown
- 2016-10-20 WO PCT/IB2016/001507 patent/WO2017068412A1/en not_active Ceased
- 2016-10-20 HR HRP20241210TT patent/HRP20241210T1/hr unknown
- 2016-10-20 FI FIEP16788794.2T patent/FI3365334T3/fi active
- 2016-10-20 ES ES16788794T patent/ES2989326T3/es active Active
- 2016-10-20 AU AU2016341520A patent/AU2016341520C1/en active Active
- 2016-10-20 HU HUE16788794A patent/HUE068392T2/hu unknown
- 2016-10-20 KR KR1020187013571A patent/KR102769567B1/ko active Active
- 2016-10-20 JP JP2018519702A patent/JP6931646B2/ja active Active
- 2016-10-20 EP EP16788794.2A patent/EP3365334B1/en active Active
- 2016-10-20 CN CN201680061146.4A patent/CN108617166B/zh active Active
- 2016-10-20 TW TW105133824A patent/TWI747846B/zh active
- 2016-10-20 SG SG10201912959QA patent/SG10201912959QA/en unknown
- 2016-10-20 LT LTEPPCT/IB2016/001507T patent/LT3365334T/lt unknown
- 2016-10-20 MY MYPI2018701450A patent/MY204050A/en unknown
- 2016-10-20 DK DK16788794.2T patent/DK3365334T3/da active
- 2016-10-20 CA CA3001799A patent/CA3001799A1/en active Pending
- 2016-10-20 SI SI201631846T patent/SI3365334T1/sl unknown
- 2016-10-20 MA MA047013A patent/MA47013A/fr unknown
- 2016-10-20 CN CN202210512050.2A patent/CN114948963B/zh active Active
- 2016-10-20 IL IL291017A patent/IL291017B2/en unknown
- 2016-10-20 PT PT167887942T patent/PT3365334T/pt unknown
-
2018
- 2018-04-12 PH PH12018500792A patent/PH12018500792A1/en unknown
- 2018-04-12 SA SA518391342A patent/SA518391342B1/ar unknown
- 2018-04-12 IL IL258662A patent/IL258662B/en unknown
-
2019
- 2019-08-15 US US16/541,863 patent/US11001575B1/en active Active
-
2021
- 2021-02-12 AU AU2021200951A patent/AU2021200951B2/en active Active
- 2021-04-07 US US17/224,733 patent/US11939321B2/en active Active
- 2021-08-13 JP JP2021132047A patent/JP7254127B2/ja active Active
-
2023
- 2023-10-19 US US18/490,403 patent/US20240368136A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5749341B2 (ja) | ピロロピリミジン化合物およびその使用 | |
| AU2014351413B2 (en) | Pyrrolopyrrolone derivatives and their use as BET inhibitors | |
| JP6934261B2 (ja) | Ｎ−（アザアリール）シクロラクタム−１−カルボキサミド誘導体、その製造方法および応用 | |
| RU2560153C2 (ru) | Триазолпиридиновые соединения, ингибирующие jak, и способы | |
| WO2012022045A1 (en) | Pyrrolopyrimidine compounds and uses thereof | |
| RU2014130125A (ru) | Новые пиррольные соединения, способ их получения и фармацевтические композиции, содержащие их | |
| BR112012011287B1 (pt) | Compostos inibidores de cinase derivados de pirolopirimidina, sua formulação farmacêutica e seus usos | |
| BR112017007769B1 (pt) | Compostos derivados de aminopirimidina, composição farmacêutica que compreende os ditos compostos e uso terapêutico dos mesmos | |
| JP2017031207A (ja) | 置換６，６−縮合窒素複素環化合物及びその使用 | |
| WO2018045957A1 (zh) | 一种cdk4/6抑制剂及其制备方法和应用 | |
| RU2014130129A (ru) | Новые фосфатные соединения, способ их получения и фармацевтические композиции, содержащие их | |
| JP7782035B2 (ja) | Ｊａｋ２阻害剤としての６－ヘテロアリールオキシベンゾイミダゾール及びアザベンゾイミダゾール | |
| EP4237418B1 (en) | Pyrimidine compounds, compositions, and medicinal applications thereof | |
| WO2022246459A1 (en) | Combination therapy | |
| EP4608820A1 (en) | Heterocyclic compounds capable of activating sting | |
| WO2021164735A1 (en) | Heteroaryl heterocyclic compounds and uses thereof | |
| JP2022550353A (ja) | アザキノリン化合物およびその使用 | |
| CN114437074A (zh) | 一种化合物、含该化合物的药物组合物及其用途 | |
| CN116323582B (zh) | 杂芳环类化合物及其用途 | |
| HK40130478A (zh) | 杂芳基杂环化合物及其用途 | |
| HK40129802A (zh) | 杂芳基杂环化合物及其用途 | |
| HK40095637B (zh) | 杂芳环类化合物及其用途 | |
| HK40130202A (zh) | 杂芳基杂环化合物及其用途 | |
| HK40094658A (zh) | 杂芳基杂环化合物及其用途 | |
| HK40094658B (zh) | 杂芳基杂环化合物及其用途 |